Danaher's (DHR) Aldevron unit and Kytopen said Tuesday they have signed a joint marketing agreement to promote the combination of the Aldveron Nanoplasmid vector technology with Kytopen's Flowfect Tx GMP cellular engineering platform.
The companies said the combination is intended to accelerate cell therapy manufacturing by improving manufacturers' CRISPR-mediated T-cell engineering workflow.
Price: 197.62, Change: +1.71, Percent Change: +0.87
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.